Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Public ClinicalTrials.gov record NCT00228969. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT00228969
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- RWJ-333369 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 79 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2005
- Primary completion
- Apr 30, 2006
- Completion
- Apr 30, 2006
- Last update posted
- Aug 1, 2012
2005 – 2006
United States locations
- U.S. sites
- 29
- U.S. states
- 19
- U.S. cities
- 29
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Huntsville | Alabama | — | — |
| Not listed | Mobile | Alabama | — | — |
| Not listed | Northport | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Irvine | California | — | — |
| Not listed | Northridge | California | — | — |
| Not listed | Sacramento | California | — | — |
| Not listed | Fort Collins | Colorado | — | — |
| Not listed | Wilmington | Delaware | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Lexington | Kentucky | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | Baton Rouge | Louisiana | — | — |
| Not listed | Golden Valley | Minnesota | — | — |
| Not listed | Saint Paul | Minnesota | — | — |
| Not listed | Chesterfield | Missouri | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Sellersville | Pennsylvania | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | El Paso | Texas | — | — |
| Not listed | Bennington | Vermont | — | — |
| Not listed | Charlottesville | Virginia | — | — |
| Not listed | Roanoke | Virginia | — | — |
| Not listed | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00228969, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 1, 2012 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00228969 live on ClinicalTrials.gov.